<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ISONIAZID- isoniazid tablet </strong><br>Mylan Institutional Inc.<br></p></div>
<h1><span class="Bold">ISONIAZID TABLETS, USP 100 mg and 300 mg</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_40b4e028-c440-4aac-bb78-2a80e88c248a"></a><a name="section-1"></a><p></p>
<p class="First">Rx<span class="Bold"></span>only</p>
<div class="Warning">
<a name="id_e7e275cf-3ed4-4574-8de4-3e3257263798"></a><a name="section-1.1"></a><p></p>
<h2>Warning</h2>
<p class="First">Severe and sometimes fatal <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> associated with isoniazid therapy has been re-</p>
<p>ported and may occur or may develop even after many months of treatment. The risk of developing <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> is age related. Approximate case rates by age are: less than 1 per 1,000 for persons under 20 years of age, 3 per 1,000 for persons in the 20-34 year age group, 12 per 1,000 for persons in the 35-49 year age group, 23 per 1,000 for persons in the 50-64 year age group, and 8 per 1,000 for persons over 65 years of age. The risk of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> is increased with</p>
<p>daily consumption of alcohol. Precise data to provide a fatality rate for isoniazid-related <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> is not available; however, in a U.S. Public Health Service Surveillance Study in- volving 13,838 persons taking isoniazid, there were 8 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> among 174 cases of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
<p>Therefore, patients given isoniazid should be carefully monitored and interviewed at monthly intervals. For persons 35 and older, in addition to monthly symptom reviews, hepatic enzymes</p>
<p>(specifically, AST and ALT (formerly <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> and SGPT, respectively)) should be measured prior to starting isoniazid therapy and periodically throughout treatment. Isoniazid-associated <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> usually occurs during the first three months of treatment. Usually, enzyme levels return to normal despite continuance of drug, but in some cases progressive liver dysfunction occurs. Other factors associated with an increased risk of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> include daily use of alcohol, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> and injection drug use. A recent report suggests an increased risk of fatal</p>
<p><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> associated with isoniazid among women, particularly black and Hispanic women. The risk may also be increased during the post partum period. More careful monitoring should be considered in these groups, possibly including more frequent laboratory monitoring. If abnor- malities of liver function exceed three to five times the upper limit of normal, discontin- uation of isoniazid should be strongly considered. Liver function tests are not a substitute for a clinical evaluation at monthly intervals or for the prompt assessment of signs or symptoms of adverse reactions occurring between regularly scheduled evaluations. Patients should be instructed to immediately report signs or symptoms consistent with <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> or other adverse effects. These include any of the following: unexplained <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, dark urine, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">icterus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, persistent <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> of the hands and feet, persistent <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> of greater than 3 days duration and/or <span class="product-label-link" type="condition" conceptid="197981" conceptname="Abdominal tenderness">abdominal tenderness</span>, especially right</p>
<p>upper quadrant <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>. If these symptoms appear or if signs suggestive of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatic damage</span> are detected, isoniazid should be discontinued promptly, since continued use of the drug in these cases has been reported to cause a more severe form of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> who have <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> attributed to isoniazid should be given appro- priate treatment with alternative drugs. If isoniazid must be reinstituted, it should be reinsti-</p>
<p>tuted only after symptoms and laboratory abnormalities have cleared. The drug should be restarted in very small and gradually increasing doses and should be withdrawn immedi-</p>
<p>ately if there is any indication of recurrent liver involvement.</p>
<p>Preventive treatment should be deferred in persons with acute <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic diseases</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b994144a-c730-49d2-a8ed-d005e97018c7"></a><a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_cf378df0-b63f-4642-bdc3-62acc5c5866b"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Isoniazid is an antibacterial available as 100 mg or 300 mg tablets for oral administration. Isoniazid is chemically known as isonicotinyl hydrazine or isonicotinic acid hydrazide. It has the following structural formula:</p>
<div class="Figure">
<a name="id352"></a><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=60a6b514-fa7f-4bc7-85b0-e5a14fa56b59&amp;name=e52d3ab7-6583-4026-b79e-7cf9c50617cb-01.jpg">
</div>
<p>Isoniazid is odorless, and occurs as a colorless or white crystalline powder or as white crystals. It is freely soluble in water, sparingly soluble in alcohol, and slightly soluble in chloroform and in ether. Isoniazid is slowly affected by exposure to air and light.</p>
<p><span class="Bold">Inactive Ingredients:</span> Colloidal silicon dioxide, crospovidone, hydrogenated vegetable oil, microcrystalline cellulose, pregelatinized starch and talc.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_01b07935-b93e-4070-9d8d-967f689fb572"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Within 1 to 2 hours after oral administration, isoniazid produces peak blood levels which decline to 50 percent or less within 6 hours. It diffuses readily into all body fluids (cerebrospinal, pleural, and ascitic fluids), tissues, organs, and excreta (saliva, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, and feces). The drug also passes through the placental barrier and into milk in concentrations comparable to those in the plasma. From 50 to 70 percent of a dose of isoniazid is excreted in the urine within 24 hours.</p>
<p>Isoniazid is metabolized primarily by acetylation and dehydrazination. The rate of acetylation is genetically determined. Approximately 50 percent of Blacks and Caucasians are "slow inacti- vators", and the rest are "rapid inactivators"; the majority of Eskimos and Orientals are" rapid inactivators."</p>
<p>The rate of acetylation does not significantly alter the effectiveness of isoniazid. However, slow acetylation may lead to higher blood levels of the drug and, thus, to an increase in toxic reactions.</p>
<p>Pyridoxine (vitamin B<span class="Sub">6</span>) deficiency is sometimes observed in adults with high doses of isoniazid and is considered probably due to its competition with pyridoxal phosphate for the enzyme apotryptophanase.</p>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_b109f0a8-80d3-4db9-b236-5c04c92c39ec"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacteri- </p>
<p>al cell wall. At therapeutic levels isoniazid is bacteriocidal against actively growing intra- </p>
<p>cellular and extracellular <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> organisms.</p>
<p><span class="Bold">Isoniazid resistant <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> bacilli develop rapidly when isoniazid monotherapy is administered.</span></p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_822e079b-1675-4991-9b11-7089f190cd5c"></a><a name="section-3.2"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Two standardized <span class="Italics">in vitro</span> susceptibility methods are available for testing isoniazid against <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> organisms. The agar proportion method (CDC or NCCLS M24-P) utilizes middlebrook 7H10 medium impregnated with isoniazid at two final concentrations, 0.2 and 0.1 mcg/mL. MIC<span class="Sub">99</span> values are calculated by comparing the quantity of organisms growing in the medium containing drug to the control cultures. Mycobacterial growth in the presence of drug ≥ 1% of the control indicates resistance.</p>
<p>The radiometric broth method employs the BACTEC 460 machine to compare the growth index from untreated control cultures to cultures grown in the presence of 0.2 and 1.0 mcg/mL of isoniazid. Strict adherence to the manufacturer’s instructions for sample processing and data interpretation is required for this assay.</p>
<p><span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> isolates with an MIC<span class="Sub">99</span> ≤ 0.2 mcg/mL are considered to be susceptible to isoniazid. Susceptibility test results obtained by the two different methods discussed above cannot be compared unless equivalent drug concentrations are evaluated.</p>
<p>The clinical relevance of <span class="Italics">in vitro</span> susceptibility for mycobacterium species other than <span class="Italics">M.</span></p>
<p><span class="Italics">tuberculos</span> is using either the BACTEC or the proportion method has not been determined.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_c2bdcf9e-8aac-4d92-a48f-251f97398d9f"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Isoniazid is recommended for all forms of tuberculos in which organisms are susceptible. However, active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> must be treated with multiple concomitant antituberculosis medications to prevent the emergence of <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>. Single-drug treatment of active tuberculos with isoniazid, or any other medication, is inadequate therapy.</p>
<p>Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>) for each group is given in parenthesis):</p>
<p>1. Persons with human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (≥ 5 mm) and persons with risk</p>
<p> factors for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> whose <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> status is unknown but who are suspected of </p>
<p> having <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>.</p>
<p>Preventive therapy may be considered for HIV infected persons who are tuberculin- negative</p>
<p>but belong to groups in which the prevalence of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is high. Candidates for</p>
<p>preventive therapy who have <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> should have a minimum of 12 months of therapy.</p>
<p>2. Close contacts of persons with newly diagnosed infectious <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (≥ 5 mm). In addition,</p>
<p> tuberculin-negative (&lt; 5mm) children and adolescents who have been close contacts of in-</p>
<p> fectious persons within the past 3 months are candidates for preventive therapy until a repeat</p>
<p> tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin</p>
<p> test is positive (&gt; 5 mm), therapy should be continued.</p>
<p>3. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year</p>
<p> period for those &lt; 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and</p>
<p> children younger than 4 years of age with a &gt; 10 mm skin test are included in this category.</p>
<p>4. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old</p>
<p> healed <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary</p>
<p> lesions consistent with healed <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or who have pulmonary <span class="product-label-link" type="condition" conceptid="442125" conceptname="Pneumoconiosis due to silica">silicosis</span> should have 12</p>
<p> months of isoniazid or 4 months of isoniazid and rifampin, concomitantly.</p>
<p>5. Intravenous drug users known to be HIV-seronegative (&gt; 10 mm).</p>
<p>6. Persons with the following medical conditions that have been reported to increase the risk of</p>
<p> <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (≥ 10 mm): <span class="product-label-link" type="condition" conceptid="442125" conceptname="Pneumoconiosis due to silica">silicosis</span>; <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus; prolonged therapy with adrenocorti-</p>
<p> costeroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases,</p>
<p> such as <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> or Hodgkin’s disease; end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>; clinical situations associated</p>
<p> with substantial rapid <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> or chronic under nutrition (including: intestinal bypass</p>
<p> surgery for <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, the postgastrectomy state (with or without <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>), chronic peptic</p>
<p> <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease, chronic <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption syndromes</span>, and carcinomas of the oropharynx and upper</p>
<p> gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive</p>
<p> therapy who have fibrotic pulmonary lesions consistent with healed <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or who have</p>
<p> pulmonary <span class="product-label-link" type="condition" conceptid="442125" conceptname="Pneumoconiosis due to silica">silicosis</span> should have 12 months of isoniazid or 4 months of isoniazid and</p>
<p> rifampin, concomitantly.</p>
<p>Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups:</p>
<dl>
<dt>1.</dt>
<dd>Foreign-born persons from high-prevalence countries who never received BCG vaccine.</dd>
<dt>2.</dt>
<dd>Medically under served low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans.</dd>
<dt>3.</dt>
<dd>Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions).</dd>
</dl>
<p>Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have &gt; 10 mm <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> from a PPD Mantoux tuberculin skin test.</p>
<p>Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> must be weighed against the risk of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis insituations where there is likelihood of serious consequences to contacts who may become infected.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_0fc3b0e1-f063-4252-a970-48f2d503325b"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Isoniazid is contraindicated in patients who develop severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including drug-induced <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>; previous isoniazid-associated hepatic injury; severe adverse reactions to isoniazid such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>; and acute liver disease of any etiology.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_ac0887e6-7c99-4365-aaf0-5a3074e4ebe2"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><a href="#i4i_warnings_id_ac0887e6-7c99-4365-aaf0-5a3074e4ebe2">See boxed warning</a>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_8fda7ab1-258f-4c09-ad1e-4aefbfc738bd"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_2597767e-4dc0-4b43-a4b9-7773787c2777"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">All drugs should be stopped and an evaluation made at the first sign of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. If isoniazid therapy must be reinstituted, the drug should be given only after symp-</p>
<p>toms have cleared. The drug should be restarted in very small and gradually increasing doses and should be withdrawn immediately if there is any indication of recurrent <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>.</p>
<p>Use of isoniazid should be carefully monitored in the following:</p>
<dl>
<dt>1.</dt>
<dd>Daily users of alcohol. Daily ingestion of alcohol may be associated with a higher incidence of + isoniazid <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</dd>
<dt>2.</dt>
<dd>Patients with active <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> or severe renal dysfunction.</dd>
<dt>3.</dt>
<dd>Age &gt; 35.</dd>
<dt>4.</dt>
<dd>Concurrent use of any chronically administered medication.</dd>
<dt>5.</dt>
<dd>History of previous discontinuation of isoniazid.</dd>
<dt>6.</dt>
<dd>Existence of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> or conditions predisposing to <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>.</dd>
<dt>7.</dt>
<dd>Pregnancy.</dd>
<dt>8.</dt>
<dd>Injection drug use.</dd>
<dt>9.</dt>
<dd>Women belonging to minority groups, particularly in the post-partum period.</dd>
<dt>10.</dt>
<dd>HIV seropositive patients.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_3205d6a2-fb63-4a37-b4e9-14ad2644997e"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Because there is a higher frequency of isoniazid associated <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> among certain patient groups, including Age &gt; 35, daily users of alcohol, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span>, injection drug use </p>
<p>and women belonging to minority groups, particularly in the post-partum period, transaminase measurements should be obtained prior to starting and monthly during preventative therapy, or more frequently as needed. If any of the values exceed three to five times the upper limit of normal, isoniazid should be temporarily discontinued and consideration given to restarting therapy.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_ce77035d-782a-402b-b780-cb10d2fee759"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fd6e5371-4d27-4267-bdff-10069486e511"></a><a name="section-7.3.1"></a><p></p>
<h3><span class="Bold">Food</span></h3>
<p class="First">Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d1de5c9c-c447-464d-98c0-dafc42ea1d70"></a><a name="section-7.3.2"></a><p></p>
<h3><span class="Bold">Acetaminophen</span></h3>
<p class="First">A report of severe acetaminophen toxicity was reported in a patient receiving isoniazid. </p>
<p>It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted in induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates acetaminophen heaptoxicity in rats <span class="Sup">1,2</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1d4769da-7dce-4485-8806-37759b85062d"></a><a name="section-7.3.3"></a><p></p>
<h3><span class="Bold">Carbamazepine</span></h3>
<p class="First">Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels. Carbamazepine levels should be determined prior to concurrent administration with isonia-</p>
<p>zid, signs and symptoms of carbamazepine toxicity should be monitored closely, and ap- propriate dosage adjustment of the anticonvulsant should be made<span class="Sup">3</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1c3ab3bc-c22d-44d1-9364-3fbede9eb35e"></a><a name="section-7.3.4"></a><p></p>
<h3><span class="Bold">Ketoconazole</span></h3>
<p class="First">Potential interaction of ketoconazole and isoniazid may exist. When ketoconazole is given in combination with isoniazid and rifampin the AUC of ketoconazole is decreased by as much as 88% after 5 months of concurrent isoniazid and rifampin therapy <span class="Sup">4</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_346f15a5-8886-4fcf-85cd-310aca78ab83"></a><a name="section-7.3.5"></a><p></p>
<h3><span class="Bold">Phenytoin</span></h3>
<p class="First">Isoniazid may increase serum levels of phenytoin. To avoid phenytoin <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, appropriate adjustment of the anticonvulsant should be made<span class="Sup">5,6</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_07907c3f-9b55-4c23-aeb4-19dfd69fafeb"></a><a name="section-7.3.6"></a><p></p>
<h3><span class="Bold">Theophylline</span></h3>
<p class="First">A recent study has shown that concomitant administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow, theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made<span class="Sup">7</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0e267097-87a8-4da3-ad6c-5236290cb0ae"></a><a name="section-7.3.7"></a><p></p>
<h3><span class="Bold">Valproate</span></h3>
<p class="First">A recent case study has shown a possible increase in the plasma level of valproate when co-administered with isoniazid. Plasma valproate concentration should be monitored when isonia-</p>
<p>zid and valproate are co-administered, and appropriate dosage adjustments of valproate should be made<span class="Sup">5</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_36733fd0-fb39-4f0b-89ec-5a4c010ee212"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis and Mutagenesis</h2>
<p class="First">Isoniazid has been shown to induce pulmonary tumors in a number of <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of mice. Isoniazid has not been shown to be carcinogenic in humans. (Note: a diagnosis of <span class="product-label-link" type="condition" conceptid="4033891" conceptname="Mesothelioma">mesothelioma</span> in a child with prenatal exposure to isoniazid and no other apparent risk factors has been reported). Iso- niazid has been found to be weakly mutagenic in <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 100 and TA 1535 of <span class="Underline"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurim</span> (Ames assay) without metabolic activation.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_e932c50d-bf47-42c0-9417-363d8bcbee7a"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_9b3c4f74-2419-452d-8b68-7038505b4d0d"></a><a name="section-7.5.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c056102-7b81-4200-9e4f-c750c039619b"></a><a name="section-7.5.1.1"></a><p></p>
<h4><span class="Bold">Pregnancy Category C</span></h4>
<p class="First">Isoniazid has been shown to have an embryocidal effect in rats and rabbits when given orally during pregnancy. Isoniazid was not teratogenic in reproduction studies in mice, rats and rabbits. There are no adequate and well-controlled studies in pregnant women. Isoniazid should be used as a treatment for active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> during pregnancy because the benefit justifies the potential risk to the fetus. The benefit of preventative therapy also should be weighed against a possible risk to the fetus. Preventive therapy generally should be started after delivery to prevent putting the fetus at risk of exposure; the low levels of isoniazid in breast milk do not threaten the neonate. Since isoniazid is known to cross the placenta barrier, neonates of isoniazid treated mothers should be carefully observed for any evidence of adverse effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_ed9df220-4f4b-491c-b631-59cf02f55963"></a><a name="section-7.5.2"></a><p></p>
<h3><span class="Bold">Nonteratogenic Effects</span></h3>
<p class="First">Since isoniazid is known to cross the placenta barrier, neonates of isoniazid-treated mothers should be carefully observed for any evidence of adverse effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_410afe08-3347-41c5-9d86-31a60637282d"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">The small concentrations of isoniazid in breast milk do not produce toxicity in the nursing newborn; therefore, breast-feeding should not be discouraged. However, because levels of isoniazid are so low in breast milk, they can not be relied upon for prophylaxis or therapy of nursing infants.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_bd98e668-ebbd-427d-8557-b318c2ba3364"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequent reactions are those affecting the nervous system and the liver.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da6f9fca-13bf-4d5d-a425-fa0e524740cb"></a><a name="section-8.1"></a><p></p>
<h2>Nervous System Reactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> is the most common toxic effect. It is dose-related, occurs most often in the malnourished and in those predisposed to <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span> (e.g., alcoholics and diabetics), and is usually preceded by <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> of the feet and hands. The incidence is higher in "slow inactivators".</p>
<p>Other neurotoxic effects, which are uncommon with conventional doses, are <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="373764" conceptname="Toxic encephalopathy">toxic encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> and <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, and toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c7b42b16-8c13-4cba-9691-f66ee4ad8c4a"></a><a name="section-8.2"></a><p></p>
<h2>Hepatic Reactions</h2>
<p class="First"><a href="#i4i_warnings_id_ac0887e6-7c99-4365-aaf0-5a3074e4ebe2">See boxed warning</a>. Elevated serum transaminase (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>; SGPT), <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="4172937" conceptname="Bilirubinuria">bilirubinuria</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and occasionally severe and sometimes fatal <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>. The common prodromal symp- toms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> are <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Mild hepatic dysfunction, evidenced by mild and transient elevation of serum transaminase levels occurs in 10 to 20 percent of patients taking isoniazid. This abnormality usually appears in the first 1 to 3 months of treatment but can occur at any time during therapy. In most instances, enzyme levels return to normal, and generally, there is no necessity to discontinue medication during the period of mild serum transaminase elevation. In occasional instances, progressive <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> occurs, with accompanying symptoms. If the <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> value exceeds three to five times the upper limit of normal, discontinuation of the isoniazid should be strongly considered. The frequency of progres- sive <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> increases with age. It is rare in persons under 20, but occurs in up to 2.3 percent of those over 50 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bcc8d6e4-62a0-49ed-8f1a-19d46bde663f"></a><a name="section-8.3"></a><p></p>
<h2>Gastrointestinal Reactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b2e46773-e538-408a-9902-f380f91c3312"></a><a name="section-8.4"></a><p></p>
<h2>Hematologic Reactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>; hemolytic, sideroblastic, or <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>; and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2425b012-26e0-4d10-9125-9c87776a2d17"></a><a name="section-8.5"></a><p></p>
<h2> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span> (morbilliform, maculopapular, purpuric, or exfoliative), <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, and <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_34b5e63e-c6fc-42e8-92cb-a246f5a1f5e9"></a><a name="section-8.6"></a><p></p>
<h2>Metabolic and Endocrine Reactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435787" conceptname="Vitamin B6 deficiency">Pyridoxine deficiency</span>, <span class="product-label-link" type="condition" conceptid="434310" conceptname="Pellagra">pellagra</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, and <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_14a217bd-62a4-44a6-9122-9a8626808793"></a><a name="section-8.7"></a><p></p>
<h2>Miscellaneous Reactions</h2>
<p class="First">Rheumatic syndrome and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>-like syndrome.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_1c49c59a-1860-47d7-80c6-43a9953374b4"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_775061c2-ae36-4254-8031-50a88e3014de"></a><a name="section-9.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">Isoniazid overdosage produces signs and symptoms within 30 minutes to 3 hours after ingestion. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, slurring of speech, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span>, and <span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span> (including bright colors and strange designs) are among the early manifestations. With marked overdosage, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, progressing rapidly from <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> to profound <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, are to be expected, along with severe, intractable <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Severe <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="4171926" conceptname="Ketonuria">acetonuria</span>, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> are typical laboratory findings.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b57c8117-d4aa-43fd-9379-6c6e2c3263b8"></a><a name="section-9.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">Untreated or inadequately treated cases of gross isoniazid overdosage, 80 mg/kg - 150 mg/kg, can cause <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span><span class="Sup">6</span> and terminate fatally, but good response has been reported in most patients brought under adequate treatment within the first few hours after drug ingestion.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_800d8ee4-1708-4844-b8c5-953d7259f947"></a><a name="section-9.2.1"></a><p></p>
<h3><span class="Bold">For the Asymptomatic Patient</span></h3>
<p class="First">Absorption of drugs from the GI tract may be decreased by giving activated charcoal. Gastric emptying should also be employed in the asymptomatic patient. Safeguard the patient’s airway when employing these procedures. Patients who acutely ingest &gt; 80 mg/kg should be treated with intravenous pyridoxine on a gram per gram basis equal to the isoniazid dose. If an unknown amount of isoniazid is ingested, consider an initial dose of 5 grams of pyridoxine given over <span class="Underline">30 to 60 minutes</span> in adults, or 80 mg/kg of pyridoxine in children.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_acd9ca7c-2183-45a7-a1da-4f69945dbe43"></a><a name="section-9.2.2"></a><p></p>
<h3><span class="Bold">For the Symptomatic Patient</span></h3>
<p class="First">Ensure adequate ventilation, support <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, and protect the airway while treating <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and attempting to limit absorption. If the dose of isoniazid is known, the patient should be treated initially with a slow intravenous bolus of pyridoxine, over 3 to 5 minutes, on a gram per gram basis, equal to the isoniazid dose. If the quantity of isoniazid ingestion is unknown, then consider an initial intravenous bolus of pyridoxine of 5 grams in the adult or 80 mg/kg in the child. If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> continue, the dosage of pyridoxine may be repeated. It would be rare that more than 10 grams of pyridoxine would need to be given. The maximum safe dose for pyridoxine in isoniazid <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> is not known. If the patient does not respond to pyridoxine, diazepam may be ad- ministered. Phenytoin should be used cautiously, because isoniazid interferes with the metabo- lism of phenytoin.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f2401fba-6ff5-48fe-badb-32330d5f85cf"></a><a name="section-9.3"></a><p></p>
<h2>General</h2>
<p class="First">Obtain blood samples for immediate determination of gases, electrolytes, BUN, glucose, etc.; type and cross-match blood in preparation for possible hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c9339315-ba02-4a42-82e8-d4151cc0c301"></a><a name="section-9.4"></a><p></p>
<h2>Rapid Control of <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span></h2>
<p class="First">Patients with this degree of INH <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> are likely to have <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>. The ad- ministration of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> under these circumstances can cause exacerbation of <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span>. Ventilation must be monitored carefully, by measuring blood <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> </p>
<p>levels, and supported mechanically, if there is <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67c9b110-8c10-4725-a4e3-e2c36111446f"></a><a name="section-9.5"></a><p></p>
<h2>Dialysis</h2>
<p class="First">Both peritoneal and hemodialysis have been used in the management of isoniazid overdosage. These procedures are probably not required if control of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> is achieved with pyridoxine, diazepam and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.</p>
<p>Along with measures based on initial and repeated determination of blood gases and other laboratory tests as needed, utilize meticulous respiratory and other intensive care to protect against <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, etc.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_685f2901-9e20-4428-b60d-89f9eeecc3dd"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION (See also INDICATIONS0.)</h1>
<p class="First">-</p>
<p><span class="Italics">NOTE</span> -- For preventive therapy of tuberculous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and treatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, it is recommended that physicians be familiar with the following publications: (1) the recommen- dations of the Advisory Council for the Elimination of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span>, published in the MMWR: vol 42; RR-4, 1993 and (2) Treatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> and <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> in Adults and Children, American Journal of Respiratory and Critical Care Medicine: vol 149; 1359-1374, 1994.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6367338e-8222-4298-9f8b-ea1efb484c88"></a><a name="section-10.1"></a><p></p>
<h2>For Treatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></h2>
<p class="First">Isoniazid is used in conjunction with other effective anti-<span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> agents. Drug susceptibility testing should be performed on the organisms initially isolated from all patients with newly diagnosed <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. If the bacilli becomes resistant, therapy must be changed to agents to which the bacilli are susceptible.</p>
<p>Usual Oral Dosage (depending on the regimen used):</p>
<p><span class="Underline">Adults:</span> 5 mg/kg up to 300 mg daily in a single dose; or 15 mg/kg up to 900 mg/day, two or</p>
<p> three times/week</p>
<p><span class="Underline">Children:</span> 10 - 15 mg/kg up to 300 mg daily in a single dose; or 20-40 mg/kg up to 900</p>
<p> mg/day, two or three times/week</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_82875427-88d7-4336-a340-246df477fdad"></a><a name="section-10.1.1"></a><p></p>
<h3><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">Pulmonary Tuberculosis</span> Without <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV Infection</span></span></h3>
<p class="First">There are 3 regimen options for the initial treatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> in children and adults:</p>
<p>Option 1: Daily isoniazid, rifampin, and pyrazinamide for 8 weeks followed by 16 weeks of </p>
<p> isoniazid and rifampin daily or 2 to 3 times weekly. Ethambutol or streptomycin</p>
<p> should be added to the initial regimen until sensitivity to isoniazid and rifampin is</p>
<p> demonstrated. The addition of a fourth drug is optional if the relative prevalence of</p>
<p> isoniazid-resistant <span class="Italics">Mycobacteriumtuberculosis</span> isolates in the community is less</p>
<p> than or equal to four percent.</p>
<p>Option 2: Daily isoniazid, rifampin, pyrazinamide, and streptomycin or ethambutol for 2</p>
<p> weeks followed by twice weekly administration of the same drugs for 6 weeks,</p>
<p> subsequently twice weekly isoniazid and rifampin for 16 weeks.</p>
<p>Option 3: Three times weekly with isoniazid, rifampin, pyrazinamide, and ethambutol or</p>
<p> streptomycin for 6 months.</p>
<p>* All regimen given twice weekly or 3 times weekly should be administered by directly observed therapy <a href="#i4i_section_id_25ed3a32-5b0e-4f14-b1fa-827b673f9b78">(see also Directly Observed Therapy</a>).</p>
<p>The above treatment guidelines apply only when the disease is caused by organisms that are sus- ceptible to the standard antituberculous agents. Because of the impact of resistance to isoniazid and rifampin on the response to therapy, it is essential that physicians initiating therapy for tu- berculosis be familiar with the prevalence of <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> in their communities. It is suggested that ethambutol not be used in children whose visual acuity cannot be monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_50d911ea-13ac-48a8-a995-710a080d7ed1"></a><a name="section-10.1.2"></a><p></p>
<h3><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">Pulmonary Tuberculosis</span> and <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV Infection</span></span></h3>
<p class="First">The response of the immunologically impaired host to treatment may not be as satisfactory as that of a person with normal host responsiveness. For this reason, therapeutic decisions for the impaired host must be individualized. Since patients co-infected with HIV may have problems with <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span>, screening of antimycobacterial drug levels, especially in patients with ad- vanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span>, may be necessary to prevent the emergence of MDRTB.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_116d6b28-a170-43d5-a69d-4554f72fb6d3"></a><a name="section-10.1.3"></a><p></p>
<h3><span class="Bold">Patients with Extra <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">Pulmonary Tuberculosis</span></span></h3>
<p class="First">The basic principles that underlie the treatment of <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> also apply to Extra pulmonary forms of the disease. Although there have not been the same kinds of carefully conducted controlled trials of treatment of Extra <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> as for pulmonary disease, increasing clinical experience indicates that a 6 to 9 month short-course regimen is effective. Because of the insufficient data, military <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, bone/joint <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, and tuberculous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> in infants and children should receive 12 month therapy.</p>
<p>Bacteriologic evaluation of Extra <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> may be limited by the relative in accessibility of the sites of disease. Thus, response to treatment often must be judged on the basis of clinical and radiographic findings.</p>
<p>The use of adjunctive therapies such as surgery and corticosteroids is more commonly required in Extra <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> than in pulmonary disease. Surgery may be necessary to obtain specimens for diagnosis and to treat such processes as <span class="product-label-link" type="condition" conceptid="312334" conceptname="Constrictive pericarditis">constrictive pericarditis</span> and <span class="product-label-link" type="condition" conceptid="4322945" conceptname="Spinal cord compression">spinal cord compression</span> from Pott’s Disease. Corticosteroids have been shown to be of benefit in preventing cardiac constriction from tuberculous <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span> and in decreasing the neurologic sequelae of all stages of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, especially when administered early in the course of the disease. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_181a7513-ffa7-450b-a982-4fd845706f5e"></a><a name="section-10.1.4"></a><p></p>
<h3><span class="Bold">Pregnant Women with <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> </span></h3>
<p class="First">The options listed above must be adjusted for the pregnant patient. Streptomycin interferes with <span class="Italics">in utero</span> development of the ear and may cause <span class="product-label-link" type="condition" conceptid="4318712" conceptname="Congenital deafness">congenital deafness</span>. Routine use of pyrazinamide is also not recommended in pregnancy because of inadequate <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> data. The initial treatment regimen should consist of isoniazid and rifampin. Ethambutol should be included unless primary isoniazid resistance is unlikely (isoniazid resistance rate documented to be less than 4%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8360aebe-6456-49e4-9dac-a607a876a718"></a><a name="section-10.1.5"></a><p></p>
<h3><span class="Bold">Treatment of Patients with Multi-Drug Resistant <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> (MDRTB)</span></h3>
<p class="First">Multiple-drug resistant <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (i.e., resistance to at least isoniazid and rifampin) presents difficult treatment problems. Treatment must be individualized and based on susceptibility studies. In such cases, consultation with an expert in <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_25ed3a32-5b0e-4f14-b1fa-827b673f9b78"></a><a name="section-10.1.6"></a><p></p>
<h3><span class="Bold">Directly Observed Therapy (DOT)</span></h3>
<p class="First">A major cause of drug-resistant <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> is patient noncompliance with treatment. The use of DOT can help assure patient compliance with drug therapy. DOT is the observation of the pa- tient by a health care provider or other responsible person as the patient ingests anti-<span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> medications. DOT can be achieved with daily, twice weekly or thrice weekly regimens, and is recommended for all patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0f0327b6-50b1-4ba7-8e49-eac39d902a06"></a><a name="section-10.2"></a><p></p>
<h2>For Preventative Therapy of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></h2>
<p class="First">Before isoniazid preventive therapy is initiated, bacteriologically positive or radiographically progressive <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> must be excluded. Appropriate evaluations should be performed if Extra <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> is suspected.</p>
<p>Adults over 30 Kg: 300 mg per day in a single dose.</p>
<p>Infants and Children: 10 mg/kg (up to 300 mg daily) in a single dose. In situations where adherence with daily preventative therapy cannot be assured, 20-30 mg/kg (not to exceed 900 mg) twice weekly under the direct observation of a health care worker at the time of admin- istration<span class="Sup">8</span>.</p>
<p>Continuous administration of isoniazid for a sufficient period is an essential part of the regimen because relapse rates are higher if chemotherapy is stopped prematurely. In the treatment of tu- berculosis, resistant organisms may multiply and the emergence of resistant organisms during the treatment may necessitate a change in the regimen.</p>
<p>For following patient compliance: the Potts-Cozart test<span class="Sup">9</span>, a simple colorimetric<span class="Sup">6</span> method of checking for isoniazid in the urine, is a useful tool for assuring patient compliance, which is essential for effective <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> control. Additionally, isoniazid test strips are also available </p>
<p>to check patient compliance.</p>
<p>Concomitant administration of pyridoxine (B<span class="Sub">6</span>) is recommended in malnourished and in those predisposed to <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> (e.g., alcoholics and diabetics).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_ee5d9bf0-247e-410d-a844-364d67f60b76"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Isoniazid Tablets, USP are available as:</p>
<p>300 mg: White to off-white, oval-shaped, scored, flat-faced, beveled-edge tablet. Debossed</p>
<p> with stylized b on one side and 071 over 300 on the other side. </p>
<p> NDC 51079-083-20 – Unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages of 100 (10 cards of 10 tablets each).</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from light and moisture.</span></p>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_f3ff694d-fc78-4823-920f-d6de02011024"></a><a name="section-11.1"></a><p></p>
<h2> References:</h2>
<dl>
<dt>1.</dt>
<dd>Murphy ,R., <span class="Italics">et al.: Annuals of InternalMedicine</span>; 1990: November 15; volume 113: 799-800.</dd>
<dt>2.</dt>
<dd>Burke, R.F., <span class="Italics">et al.: Res Commum ChemPathol Pharmacol</span>. 1990; July; vol. 69; 115-118.</dd>
<dt>3.</dt>
<dd>Fleenor, M.F., <span class="Italics">et al.:Chest</span> (United States) <span class="Italics">Letter</span>,; 1991: June; 99 (6): 1554.</dd>
<dt>4.</dt>
<dd>Baciewicz, A.M. and Baciewicz ,Jr. F.A.,: Arch Int Med 1993, September; vol- ume 153; 1970-1971.</dd>
<dt>5.</dt>
<dd>Jonville, A.P., <span class="Italics">et al.: European Journal of Clinical Pharmacol (Germany)</span>, 1991: 40 (2) p198.</dd>
<dt>6.</dt>
<dd>American Thoracic Society/Centers for Disease Control: Treatment of Tubercu- losis and <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> in Adults and Children. Amer. J. Respir Crit Care Med. 1994; 149: p1359-1374.</dd>
<dt>7.</dt>
<dd>Hoglund P., <span class="Italics">et al.: European Journal of Respir Dis</span> (Denmark) 1987: February; 70 (2) p110-116.</dd>
<dt>8.</dt>
<dd>Committee on infectious Diseases American Academy of Pediatrics: 1994, Red Book: Report of the Committee on Infectious Diseases; 23 edition; p487.</dd>
<dt>9.</dt>
<dd>Schraufnagel, DE; <span class="Italics">Testing for Isoniazid; Chest</span> (United States) 1990, August; 98 (2) p314-316.</dd>
</dl>
<p class="First">Manufactured by:<br><span class="Bold">Barr Laboratories, Inc.</span><br>Pomona, NY 10970</p>
<p>Manufactured for:<br><span class="Bold">Teva Pharmaceuticals USA<br></span>Sellersville, PA 18960 </p>
<p>Distributed by:<br><span class="Bold">Mylan Institutional Inc.<br></span>Rockford, IL 61103 U.S.A.</p>
<p>S-4001 R12<br>10/12</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_13dfa323-5f57-4bf0-b1ef-5aaac2c0209e"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL – 300 mg</h1>
<p class="First">NDC 51079-083-20</p>
<p><span class="Bold">Isoniazid<br>Tablets, USP<br>300 mg</span></p>
<p>100 Tablets (10 x 10)</p>
<p>Each tablet contains 300 mg isoniazid.</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>prescribing information.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).<br>[See USP Controlled Room Temperature.]<br>Protect from light and moisture.</span></p>
<p>Manufactured by:<br><span class="Bold">Barr Laboratories, Inc.</span><br>Pomona, NY 10970</p>
<p>Manufactured for:<br><span class="Bold">Teva Pharmaceuticals USA<br></span>Sellersville, PA 18960</p>
<p><span class="Bold">Rx only</span></p>
<p>S-5175 R10</p>
<p>Packaged and Distributed by:</p>
<p><span class="Bold">Mylan Institutional Inc.</span></p>
<p>Rockford, IL 61103 U.S.A.</p>
<p>This unit dose package is not child resistant.</p>
<p>For institutional use only.</p>
<p>Keep this and all drugs out of the reach of children.</p>
<p>This container provides light-resistance.</p>
<p>See window for lot number and expiration date.</p>
<div class="Figure">
<a name="id2047486476"></a><img alt="Isoniazid 300 mg Tablets Unit Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=60a6b514-fa7f-4bc7-85b0-e5a14fa56b59&amp;name=image-01.jpg">
</div>
<div class="Figure">
<a name="id-1016927409"></a><img alt="Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=60a6b514-fa7f-4bc7-85b0-e5a14fa56b59&amp;name=image-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ISONIAZID 		
					</strong><br><span class="contentTableReg">isoniazid tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51079-083(NDC:0555-0071)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ISONIAZID</strong> (ISONIAZID) </td>
<td class="formItem">ISONIAZID</td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">b;071;300</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-083-20</td>
<td class="formItem">100  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-083-01</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA080937</td>
<td class="formItem">06/09/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Institutional Inc.
							(039615992)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a3284647-5eb1-4f9d-b14f-3f357ed0e3eb</div>
<div>Set id: 60a6b514-fa7f-4bc7-85b0-e5a14fa56b59</div>
<div>Version: 2</div>
<div>Effective Time: 20121005</div>
</div>
</div> <div class="DistributorName">Mylan Institutional Inc.</div></p>
</body></html>
